Viridian Therapeutics Prices $350M in Concurrent Public Offerings

Viridian Therapeutics (NASDAQ:VRDN) has priced upsized concurrent public offerings totaling $350 million, including convertible notes and an equity offering. The company plans to use the proceeds to repay existing debt and fund research and development.

By Maham Fatima Thu, May 21, 2026 at 4:30 PM GMT+3 2 min read · Yahoo Finance · May 21, 2026, 13:30 UTC

Viridian Therapeutics Prices $350M in Concurrent Public Offerings

Tickers: $VRDN

Topics: convertible notes debt repayment stock offerings

Read the full article at Yahoo Finance

More World news

Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC